<DOC>
	<DOCNO>NCT02136524</DOCNO>
	<brief_summary>This study Phase 1 , open-label , randomize , 2-period , 2-treatment sequence crossover study determine relative bioavailability cobimetinib administer single dose tablet formulation relative single dose capsule formulation healthy male female participant . A minimum 24 participant ( 12 participant per sequence ) complete study . Participants randomly assign 2 possible sequence ( i.e. , I : A/B , II : B/A ) treatment follow : Treatment A : One cobimetinib tablet administer single oral dose least 8-hour fast ; Treatment B : Four cobimetinib capsule administer single oral dose least 8-hour fast . The study expect last approximately 7 week .</brief_summary>
	<brief_title>A Randomized , Phase I , Cross-Over Study Assess Relative Bioavailability Single-Dose Cobimetinib ( GDC-0973 ) Tablet v . Capsule Formulation</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer 18 55 year age , inclusive Body mass index 18.5 32.0 kg/m2 , inclusive ; Adequate renal , liver , hematologic function Participants good health determine clinically significant finding medical history , 12lead ECG , vital sign , clinical laboratory evaluation Significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>